地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:13212737804
传真:18771997407
邮箱:sales@amyjet.com
<艾美捷科技代理42 life sciences品牌全系列产品
42 life sciences是一家位于德国北部不来梅港的中小型企业。42 life sciences专注于开发和生产用于免疫组化(IHC)及原位杂交(ISH)应用的创新试剂。公司的核心优势在于拥有经验丰富的生物技术专家团队,确保产品开发高效聚焦,同时以可靠且具成本效益的方式进行生产。所有研发与制造流程均在我们自有设施中严格遵循EN ISO9001和EN ISO 13485标准执行。
42 life sciences公司的产品与服务包括:免疫组化与原位杂交创新试剂;外包生物缓冲液及试剂的生产业务。

▎42 life sciences产品列表
| 分类 | 品名 | 产品描述 | 货号 | 规格 |
| Chromogens for HRP | AEC Solution IHC (ready-to-use) | AEC (3-Amino-9-Ethylcarbazole) is a commonly used chromogen for immunohistochemical (IHC) procedures supplied in one liquid component. | S-99012-100;S-99012-1000 | 100ml;1000ml |
| Chromogens for HRP | AEC Solution ISH (ready-to-use) | AEC (3-Amino-9-Ethylcarbazole) is a commonly used chromogen for chromogenic in situ hybridization (CISH) procedures supplied in one liquid component. | S-99010-500;S-99010-1000 | 500ml;1000ml |
| Chromogens for HRP | DAB Solution Set (2 components) | DAB (3,3‘-diaminobenzidine) is a widely used chromogen in immunohistochemical and immunoblotting applications. | S-99014-103;S-99014-1030 | 103ml;1030ml |
| Chromogens for HRP | HRP-Green Solution Set (2 components) | The HRP-Green Solution Set is a new chromogen used in immunohistochemical and chromogenic in situ hybridization applications. | S-99056-103;S-99056-1030 | 103ml;1030ml |
| Chromogens for HRP | HRP-Green Solution Set (MxE) | The HRP-Green Solution Set (MxE) is a unique chromogen used in immunohistochemical and chromogenic in situ hybridization applications that is mixable in equal parts. | S-99070-100;S-99070-2000 | 100ml;2000ml |
| Chromogens for HRP | AP-Red Solution Set IHC (2 components) | The AP-Red Solution Set IHC is a chromogen used in immunohistochemical applications. | S-99065-103 | 103ml |
| Chromogens for HRP | AP-Red Solution Set ISH (2 components) | The AP-Red Solution Set ISH is a chromogen used in chromogenic in situ hybridization applications. | S-99061-1030 | 1030ml |
| Chromogens for HRP | NBT/BCIP Solution (ready-to-use) | The NBT/BCIP Solution is a chromogen used in immunohistochemical and chromogenic in situ hybridization applications. | S-99064-500 | 500ml |
| Counterstains | Mayer`s Hematoxylin Solution (ready-to-use) | Mayer’s Hematoxylin Solution is a staining reagent for histological applications. | S-99025-1000 | 1000ml |
| Counterstains | Nuclear Blue Solution (ready-to-use) | Nuclear Blue Solution is a hematoxylin based reagent for counterstaining applications in in situ hybridization (ISH) and immunohistochemistry (IHC) procedures using common chromogens like AEC and DAB. | S-99035-1000 | 1000ml |
| Counterstains | Nuclear Fast Red Solution (ready-to-use) | Nuclear Fast Red Solution is designed for use as a counterstaining solution in immunohistochemistry (IHC) procedures using common chromogens like BCIP/NBT. | S-99031-1000 | 1000ml |
| Counterstains | Nuclear Red Solution (ready-to-use) | Nuclear Red Solution is a nuclear fast red (a.k.a. Kernechtrot) based reagent for counterstaining applications in in situ hybridization (ISH) and immunohistochemistry (IHC) procedures. | S-99033-500;S-99033-1000 | 500ml;1000ml |
| Counterstains | Nuclear Green Solution (ready-to-use) | Ready-to-use Nuclear Green Solution optimized for the use in immunohistochemical (IHC) and in situ hybrididzation (ISH) procedures. Suitable for aqueous and non- aqueous mountants. | S-99104-1000 | 1000ml |
| Ancillary Reagents | 1% BSA Ab Diluent (ready-to-use) | The 1% BSA Ab Diluent is a stabilizer and diluent for all antibodies routinely used in immunohistochemistry (IHC) and in situ hybridization (ISH) applications. | S-99068-1000 | 1000ml |
| Ancillary Reagents | one4all-Antibody Stabilizer (ready-to-use) | The one4all-Antibody Stabilizer is a unique stabilizer for all antibody-enzyme conjugates routinely used in immunohistochemistry (IHC) and in situ hybridization (ISH) applications as well as in ELISA. | S-99030-1000 | 1000ml |
| Ancillary Reagents | Pepsin Solution (ready-to-use) | Pepsin is a commonly used digestive enzyme for immunohistochemical (IHC) and in situ hybridization (ISH) procedures. | S-99003-50;S-99003-500;S-99003-1000 | 50ml;500ml;1000ml |
| Ancillary Reagents | Pepsin Solution for Cytology (ready-to-use) | Pepsin Solution for Cytology is a digestive enzyme solution used in in situ hybridization (ISH) procedures in cytology specimens. | S-99053-500;S-99053-1000 | 500ml;1000ml |
| Ancillary Reagents | Proteinase K Solution (ready-to-use) | The Proteinase K Solution is specifically designed for use in the pretreatment of formalin-fixed tissue for in situ-hybridization (ISH) procedures. | S-99080-100 | 100ml |
| Ancillary Reagents | DuraTect™ DAPI/Antifade Solution (ready-to-use) | The DuraTect™ DAPI/Antifade Solution is a refrigerator-stable formula for preserving fluorescence. | S-99081-10;S-99081-100;S-99081-500 | 10ml;100ml;500ml |
| Ancillary Reagents | DuraTect™ DAPI/Antifade Solution "ultra" (ready-to-use) | The DuraTect™ DAPI/Antifade Solution "ultra" is a refrigerator-stable formula for preserving fluorescence. | S-99098-50 | 50ml |
| Ancillary Reagents | COT-DNA, human (10mg/ml) | The COT fraction of human genomic DNA predominantly consists of rapidly annealing repetitive sequences. | S-99040-1;S-99040-10;S-99040-50 | 1mg;10mg;50mg |

艾美捷科技代理HycultBiotech全系列产品。
Hycult Biotech是一家专注于设计、研发、生产以及销售抗体和其相关产品的公司,其特色产品是天然免疫及相关领域的免疫分析试剂,例如补体, 嗜中性粒细胞蛋白,TLP,清道夫受体以及急性期蛋白等。除此之外,Hycult Biotech公司也可以提供炎症反应和细胞损伤等方面的产品。
HYCULT BIOTECH的主要产品包括:
Assays
Monoclonal antibodies
Polyclonal antibodies
Disease state human plasma
Proteins
Functional study antibodies
Immunoassay antibodies
Secondary reagents
按照产品领域细分:
Acute phase proteins
Adhesion molecules
Antimicrobial peptides
Cell damage and toxicity
Coagulation molecules
Complement and collectins
Cytokines and chemokines
Granulocyte and lymphocyte proteins
LPS and microbial toxins
Oxidative stress
TLR and inflammasome
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
< " data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Hycult Biotech"> Hycult Biotech
QED Bioscience致力于为生物医药行业提供各类高品质抗体。
QED Bioscience has been designing and manufacturing antibodies for over 20 years, and throughout our history, our goals have remained unchanged: provide the best antibody products and services on the market and support our clients with the expertise and assistance they should expect from a full-spectrum antibody company like QED.
QED Bioscience develops novel monoclonal and polyclonal antibody products for our academic, biotechnology, diagnostic and pharmaceutical research clients. We develop these antibodies using the client’s small molecule, protein, or peptide targets, or by utilizing the target cDNA. We are a full-service corporation, and offer additional immunochemistry services such as purification and conjugation so that we can provide our clients with an antibody product that will work specifically within their system. We also develop monoclonal antibodies with pharmacological activity for enzyme neutralization and inhibition of receptor-ligand interactions, and anti-idiotypic antibodies.
QED Bioscience的主要产品包括:
Agriculture and Food Science Antibodies
Anti-Immunoglobulin Antibodies
Apoptosis Antibodies
Autophagy Antibodies
BioWarfare Antibodies
Cancer Research Antibodies
Cell Adhesion Molecule Antibodies
Coagulation Factor Antibodies
DNA/RNA/Oxidative Stress Antibodies
Drug Antibodies
Enzymes and Enzyme Inhibitor Antibodies
Epitope Tag Antibodies
Growth Factors/Cytokines/Receptor Antibodies
Heat Shock and Stress Protein Antibodies
Hormones and Serum Protein Antibodies
Infectious Disease Antibodies
Ion Channel Antibodies
Matrix Protein/MMP Antibodies
Neuroscience and Signal Transduction Antibodies
Phospho-specific Antibodies
Protein Transcription Antibodies
Reproductive Biology Antibodies
Secondary Antibodies
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

艾美捷科技特约代理Enzyme Research Laboratories公司产品。
Enzyme Research Laboratories公司在过去的30年中已生产和销售多种用于基础研究的凝血酶和辅因子。通过不断追求最优质的产品,赢得了信任,Enzyme Research Laboratories通过提供单克隆抗体和多克隆抗体服务于科学研究和临床诊断领域。
For over 30 years Enzyme Research Laboratories has been manufacturing and distributing a variety of enzymes and cofactors used in basic coagulation research. By constantly striving for products of utmost quality, ERL has earned the trust of coagulation research communities worldwide. ERL is dedicated to serving the research and diagnostic communities by offering a complementary line of monoclonal and polyclonal antibodies.
Enzyme Research Laboratories公司的主要产品包括:
Monoclonal
Polyclonal
Paired Antibodies
Snake Venom Protein
PC Activator
Factor X Activator-RVV
Canine Proteins
Murine Proteins
Porcine Proteins
Rabbit Proteins
Rat Proteins
Des-Gla Proteins
按照研究领域细分:
Zymogens
Enzymes
CoFactors
Inhibitors
Human Fibrinogen
产品清单包括:
| Human Coagulation | |||
| 分类 | 产品清单 | 编号 | 规格 |
| Human Coagulation-Zymogens | Human Prothrombin | HP 1002 | 9.0 mg, 90 mg |
| Human Factor VII | HFVII 1007 | 0.1 mg, 1.0 mg | |
| Human Protein C | HPC 1001 | 0.1 mg, 1.0 mg | |
| Human Factor IX | HFIX 1009 | 0.5 mg | |
| Human Factor X | HFX 1010 | 0.8 mg | |
| Human Factor XI | HFXI 1111 | 0.1 mg, 1.0 mg | |
| Human Factor XIII | HFXIII 1313 | 0.25 mg, 1.0 mg | |
| Human Factor XII | HFXII 1212 | 0.5 mg, 1.0 mg | |
| Human Prekallikrein | HPK 1302 | 1.0 mg | |
| Sing. Chain High Molecular Wt. Kininogen | HK 1300 | 1.0 mg | |
| Two Chain High Molecular Wt. Kininogen | 2HK 1301 | 1.0 mg | |
| Human Glu-Plasminogen | HPg 2001 | 1.0 mg | |
| Human Lys-Plasminogen | LPg 2002 | 1.0 mg | |
| Human Coagulation-Enzymes | Human Alpha Thrombin | HT 1002a | 1000 units |
| Human Gamma Thrombin | HGT | 1.0 mg | |
| Human Factor VIIa | HFVIIa | 0.1 mg, 1.0 mg | |
| Human Activated Protein C | APC | 0.1 mg, 1.0 mg | |
| Human Factor IXa Beta | HFIXa 1080 | 0.5 mg | |
| Human Factor Xa | HFXa 1011 | 0.8 mg | |
| Human Factor XIa | HFXIa 1111a | 0.1 mg, 1.0 mg | |
| Human Factor Alpha-XIIa | HFXIIa 1212a | 0.5 mg, 1.0 mg | |
| Human Factor XIIa beta | HFXIIab | 0.1 mg, 1.0 mg | |
| Human Factor XIIIa | HFXIIIa 1314 | 0.25 mg, 1.0 mg | |
| Human Kallikrein | HPKa 1303 | 1.0 mg | |
| Human Plasmin | HPlasmin | 1.0 mg | |
| Human Coagulation-CoFactors | Human Protein S | HPS | 1.0 mg |
| Human Protein Z | HPZ | 0.5 mg | |
| Human Fibronectin | FN | 1.0 mg | |
| Human Coagulation-Inhibitors | Alpha2-Antiplasmin | α2AP | 0.1 mg, 1.0 mg |
| Corn Trypsin Inhibitor | CTI | 1.0 mg | |
| Human Antithrombin | HAT | 1.0 mg | |
| Human Coagulation-Platelets & Plasma Proteins | Human GPIIbIIIa | GP2b3a | 1.0 mg |
| Platelet Factor 4 | PF4 | 0.1 mg | |
| Apolipoprotein | HAPO-H | 0.1 mg | |
| Human Coagulation-Human Fibrinogen | Human Fibrinogen 1, 2, & 3 | FIB 1, FIB 2, FIB 3 | 1.0 gram |
| Peak 1 Fib (XIII free) | P1 FIB | 10.0 mg | |
| Peak 2 Fibrinogen | P2 FIB | 10 mg | |
<<
| Bovine Coagulation | |||
| 分类 | 产品清单 | 编号 | 规格 |
| Bovine Coagulation-Zymogens | Bovine Protein C | BPC 1003 | 1.0 mg |
| Bovine Prothrombin | BP 1004 | 10 mg | |
| Bovine Factor IX | BFIX 1005 | 0.5 mg | |
| Bovine Factor X | BFX 1006 | 1.0 mg | |
| Bovine Plasminogen | BPG | 1.0 mg | |
| Bovine Coagulation-Enzymes | Bovine Activated Protein C | BPCa | 0.1 mg |
| Bovine Alpha-Thrombin | BT 1002a | 1000 units | |
| Bovine Factor IXa Beta | BFIXa 1080 | 0.5 mg | |
| Bovine Factor Xa | BFXa | 1.0 mg | |
| Bovine Factor XIa | BFXIa 11a | 1.0 mg | |
| Bovine Coagulation-CoFactors | Bovine Factor V/Va | BFV/Va | 1.0 mg, 5.0 mg |
| Bovine Coagulation-Inhibitors | Bovine Antithrombin | BAT | 1.0 mg |
| Bovine Coagulation-Platelets & Plasma Proteins | Bovine Fibrinogen, Plasminogen Depleted | BFIB1 | 1.0 gram |
| Antibodies | |||
| 分类 | 产品清单 | 编号 | 规格 |
| Antibodies-Monoclonal | Anti-Human Factor V | Mab HFV | 0.1 mg , 0.5 mg |
| Anti-Human Factor VII | Mab HFVII | 0.1 mg , 0.5 mg | |
| Anti-Human Factor VIII | Mab HFVIII | 0.1 mg , 0.5 mg | |
| Anti-Human Factor VIII | Mab HFVIII-8001 | 0.1 mg , 0.5 mg | |
| Anti-Human Factor VIII | Mab HFVIII-8011 | 0.1 mg , 0.5 mg | |
| Anti-Human Factor VIII | Mab HFVIII-8002 | 0.1 mg , 0.5 mg | |
| Anti-Human Factor VIII | Mab HFVIII-8040 | 0.1 mg , 0.5 mg | |
| Anti-Human Factor IX | Mab HFIX | 0.1 mg , 0.5 mg | |
| Anti-Human Factor IX | Mab HFIX-102 | 0.1 mg , 0.5 mg | |
| Anti-Human Factor IX | Mab HFIX-001 | 0.1 mg , 0.5 mg | |
| Anti-Human Factor X | Mab HFX | 0.1 mg , 0.5 mg | |
| Anti-Human Factor X Light Chain | Mab HFX-LC | 0.1 mg , 0.5 mg | |
| Anti-Human Factor X Heavy Chain | Mab HFX-HC | 0.1 mg , 0.5 mg | |
| Anti-Human Factor XI | Mab HFXI | 0.1 mg , 0.5 mg | |
| Anti-Human Factor XII | Mab HFXII | 0.1 mg , 0.5 mg | |
| Anti-Human Factor XIII | Mab HFXIII | 0.1 mg , 0.5 mg | |
| Anti-Human Antithrombin | Mab HAT | 0.1 mg , 0.5 mg | |
| Anti-Thrombin | Mab IIa | 0.1 mg , 0.5 mg | |
| Anti-Human Prothrombin | Mab HFII | 0.1 mg , 0.5 mg | |
| Anti-Human Protein C | Mab HPC | 0.1 mg , 0.5 mg | |
| Anti-Human Tissue Factor | Mab TFE | 0.1 mg , 0.5 mg | |
| Anti-Human vWF | Mab VWF | 0.1 mg , 0.5 mg | |
| Anti-Human GPIIbIIIa | Mab GP2b3a | 0.1 mg , 0.5 mg | |
| Anti-Plasminogen | Mab HPG-030 | 0.1 mg , 0.5 mg | |
| Anti-Plasminogen | Mab HPG | 0.1 mg , 0.5 mg | |
| Anti-Vitronectin | Mab VN | 0.1 mg , 0.5 mg | |
| Anti-C4 Binding Protein | Mab C4BP | 0.1 mg , 0.5 mg | |
| Anti-PA Kringle 4 | Mab PA K4 | 0.1 mg , 0.5 mg | |
| Anti-PA Kringle 1-4 | Mab PA K1-4 | 0.1 mg , 0.5 mg | |
| Anti-PA Kringle 1-3 | Mab PA K1-3 | 0.1 mg , 0.5 mg | |
| Anti-Human Fibrinogen | Mab FIB | 0.1 mg , 0.5 mg | |
| Anti-Tissue Plasminogen Activator | Mab TPA | 0.1 mg , 0.5 mg | |
| Antibodies-Polyclonal | Sheep, purified IgG | SAFG-IG | 10 mg |
| Sheep, affinity purified, IgG | SAFG-AP | 0.5 mg | |
| Sheep, peroxidase conjugated. IgG | SAFG-HRP | 0.2 mg | |
| Sheep, affinity purified peroxidase conjugated 0.1 mg | SAFG-APHRP | 0.1 mg | |
| sheep, affinity purified IgG | *SARFG-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG | *SARFG-HRP | 0.2 mg | |
| Sheep, purified IgG | *SAFGP-IG | 5 mg | |
| Sheep, peroxidase conjugated IgG | *SAFGP-HRP | 0.2 mg | |
| Sheep, purified IgG | SAFNE-IG | 10 mg | |
| Sheep, peroxidase conjugated. IgG | *SAFNE-HRP | 0.2 mg | |
| sheep, purified IgG | *SAFPA-IG | 10 mg | |
| sheep, affinity purified IgG | *SAFPA-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG | *SAFPA-HRP | 0.2 mg | |
| sheep, purified IgG | SAFII-IG | 10 mg | |
| sheep, affinity purified IgG | SAFII-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG | SAFII -HRP | 0.2 mg | |
| sheep, Prothrombin Fragment-1, affinity purified IgG | SAFII-F1AP | 0.5 mg | |
| sheep, Prothrombin Fragment-2, affinity purified IgG | SAFII-F2AP | 0.5 mg | |
| sheep, purified IgG | SAHT-IG | 10 mg | |
| sheep, affinity purified IgG, (Prothrombin Adsorbed) | SAHT-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG | SAHT-HRP | 0.2 mg | |
| sheep, purified IgG | *SABT-IG | 10 mg | |
| sheep, affinity purified IgG | SABT-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG | *SABT-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | *SART-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | *SART-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | *SART-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | SAFV-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAFV-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAFV-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | SAFVII-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAFVII-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAFVII-HRP | 0.2 mg | |
| sheep, affinity purified IgG Fluorescein Conjugate, 0.1 mg | *SAFVII-APFTC | 0.1 mg | |
| sheep, purified IgG, 10 mg | SAF8C-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAF8C-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAF8C-HRP | 0.2 mg | |
| sheep, affinity purified IgG Fluorescein Conjugate, 0.1 mg | *SAF8C-APFTC | 0.1 mg | |
| sheep, purified IgG, 5 mg | SAC8C-IG | 5mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | *SAC8C-HRP | 0.2 mg | |
| goat, purified IgG, 10 mg | GAFIX-IG | 10 mg | |
| goat, affinity purified IgG, 0.5 mg | GAFIX-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GAFIX-HRP | 0.2 mg | |
| goat, peroxidase conjugated affinity purified IgG, 0.1 mg | GAFIX-APHRP | 0.1 mg | |
| goat, affinity purified IgG Fluorescein Conjugate, 0.1mg | *GAFIX-APFTC | 0.1 mg | |
| sheep, purified IgG, 10 mg | SAFIX-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAFIX-AP | 0.5 mg | |
| sheep, peroxidase conjugated affinity purified IgG, 0.1 mg | SAFIX-APHRP | 0.1 mg | |
| goat, purified IgG, 10 mg | GAFX-IG | 10 mg | |
| goat, affinity purified IgG, 0.5 mg | GAFX-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GAFX-HRP | 0.2 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAFX-AP | 0.5 mg | |
| rabbit, peroxidase conjugated IgG, 0.2 mg | RAFX-HRP | 0.2 mg | |
| goat, purified IgG, 5 mg | GAFXI-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GAFXI-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GAFXI-HRP | 0.2 mg | |
| sheep, purified IgG, 5.0 mg | SAFXI-IG | 5.0 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAFXI-AP | 0.5 mg | |
| goat, purified IgG, 5 mg | GAFXII-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GAFXII-AP | 0.5 mg | |
| goat peroxidase conjugated IgG, 0.2 mg | GAFXII-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | SAFXIII-IG | 10 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAFXIII-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | SAF13A-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAF13A-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | *SAF13A-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | SAPK-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAPK-AP | 0.5 mg | |
| sheep, HRP-AP IgG, 0.1 mg | SAPK-APHRP | 0.1 mg | |
| goat, purified IgG, 5 mg | *GAPC-IG | 0.5 mg | |
| goat, affinity purified IgG, 0.5 mg | GAPC-AP | 0.5 mg | |
| sheep, purified IgG, 10 mg | SAPC-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAPC-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAPC-HRP | 0.2 mg | |
| goat, purified IgG, 5 mg | GAPS-IG | 5mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GAPS-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | SAPS-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAPS-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAPS-HRP | 0.2 mg | |
| goat, purified IgG, 5 mg | *GAPG-IG | 0.5 mg | |
| goat, affinity purified IgG, 0.5 mg | *GAPG-AP | 0.5 mg | |
| goat, peroxidase conjugated affinity purified IgG, 0.1 mg | GAPG-APHRP | 0.1mg | |
| sheep, purified IgG, 5 mg | *SAPG-IG | 5 mg | |
| sheep, affinity purified IgG, 0.5 mg | *SAPG-AP | 0.5 mg | |
| sheep, purified IgG, 10 mg | *SAPAI-IG | 10 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAPAI-HRP | 0.2mg | |
| sheep, affinity purified IgG, 0.5 mg | SATAFI-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SATAFI-HRP | 0.2mg | |
| sheep, purified IgG, 10 mg | *SATPA-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SATPA-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SATPA-HRP | 0.2mg | |
| sheep, purified IgG, 10 mg | *SAAT-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAAT-AP | 0.5 mg | |
| sheep, peroxidase conjugated affinity purified IgG, 0.1 mg | SAAT-APHRP | 0.1mg | |
| goat, purified IgG, 10 mg | *GAAT-IG | 10 mg | |
| goat, affinity purified IgG, 0.5 mg | GAAT-AP | 0.5 mg | |
| goat, purified IgG, 5 mg | *GAHC2-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GAHC2-AP | 0.5 mg | |
| goat, peroxidase conjugated affinity purified IgG, 0.2 mg | *GAHC2-APHRP | 0.2mg | |
| goat, affinity purified IgG, 0.5 mg | *GAPCI-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | *GAPCI-HRP | 0.2mg | |
| goat, purified IgG, 5 mg | *GA2AP-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GA2AP-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GA2AP-HRP | 0.2mg | |
| sheep, purified IgG, 10 mg | SA2AP-IG | 10 mg | |
| sheep, purified IgG, 10 mg | *SA1AT-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | *SA1AT-AP | 0.5 mg | |
| sheep, peroxidase conjugated -affinity purified IgG, 0.1 mg | SA1AT-APHRP | 0.1mg | |
| goat, purified IgG, 10 mg | *GA1AT-IG | 10 mg | |
| goat, affinity purified IgG, 0.5 mg | GA1AT-AP | 0.5 mg | |
| goat, purified IgG, 10 mg | *GAA2M-IG | 10 mg | |
| goat, affinity purified IgG, 0.5 mg | GAA2M-AP | 0.5 mg | |
| goat, peroxidase conjugated-affinity purified IgG, 0.1 mg | *GAA2M-APHRP | 0.1mg | |
| sheep, purified IgG, 10 mg | *SAPF4-IG | 10 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAPF4-HRP | 0.2mg | |
| goat, purified IgG, 5 mg | *GAB2G-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GAB2G-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GAB2G-HRP | 0.2mg | |
| goat, purified IgG, 2.5 mg | GAVWF-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GAVWF-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.15 mg | GAVWF-HRP | 0.1mg | |
| sheep, purified IgG, 5 mg | SACWF-IG | 5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SACWF-HRP | 0.2mg | |
| sheep, purified IgG, 5 mg | SARTW-IG | 5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SARTW-HRP | 0.2mg | |
| sheep, purified IgG, 10 mg | SATF-IG | 10 mg | |
| sheep, peroxidase conjugated, 0.2 mg | *SATF-HRP | 0.2mg | |
| mouse, Fluorescein Conjugate, 0.1 mg | MATF-FITC | 0.1mg | |
| sheep, purified IgG, 10 mg | *SATFPI-IG | 10 mg | |
| sheep, purified IgG, 10 mg | *SAVN-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAVN-AP | 0.5 mg | |
| sheep, peroxidase conjugated affinity purified, 0.1 mg | SAVN-APHRP | 0.1mg | |
| goat, purified IgG, 5 mg | GACINH-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GACINH-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GACINH-HRP | 0.2mg | |
| sheep, purified IgG, 10 mg | *SANE-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SANE-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SANE-HRP | 0.2mg | |
| sheep, purified IgG, 10 mg | SA2B3A-IG | 10 mg | |
| sheep, peroxidase conjugated affinity purified IgG, 0.5 mg | SAR-APHRP | 0.5 mg | |
| -Rabbit non-immune IgG, 10 mg | NIR-IG | 10 mg | |
| -Sheep non-immune IgG, 20 mg | NIS-IG | 20mg | |
| -Sheep non-immune FITC, 0.1 mg | *NIS-FITC | 0.1mg | |
| -Goat non-immune IgG, 10 mg | NIG-IG | 10 mg | |
| donkey, peroxidase conjugated affinity purified IgG, 0.5 mg | DAS-APHRP | 0.5 mg | |
| Antibodies-Paired Antibodies | von Willebrand Factor | VWF-EIA | - |
| Factor V | FV-EIA | - | |
| Factor VII | FVII-EIA | - | |
| Factor VIII:C | FVIII:C-EIA | - | |
| Factor IX | FIX-EIA | - | |
| Factor X | FX-EIA | - | |
| Factor XI | FXI-EIA | - | |
| Factor XII | FXII-EIA | - | |
| Factor XIII | FXIII-EIA | - | |
| Prothrombin | FII-EIA | - | |
| Protein S | PS-EIA | - | |
| Protein C | PC-EIA | - | |
| Alpha 1 Antitrypsin | A1AT-EIA | - | |
| Antithrombin III | ATIII-EIA | - | |
| Thrombin-Antithrombin Complex | TAT-EIA | - | |
| Plasminogen | PG-EIA | - | |
| Tissue Plasminogen Activator | TPA-EIA | - | |
| Fibrinogen | FG-EIA | - | |
| Apolipoprotein-H (B2-Glycoprotein) | APOH-EIA | - | |
| Canine Factor VIII | CFVIII-EIA | - | |
| Canine Factor IX | CFIX-EIA | - | |
| Prekallikrein | PK-EIA | - | |
| Substrates | |||
| 分类 | 产品清单 | 编号 | 规格 |
| Substrates-Substrates | PlasminChrom | 100-01 | 5mg |
| Substrates-Substrates | ThrombinChrom | 100-02 | 5mg |
| Substrates-Substrates | RGR-XaChrom | 100-03 | 5mg |
| Snake Venom Protein | |||
| 分类 | 产品清单 | 编号 | 规格 |
| Snake Venom Protein | Factor X Activator-RVV | RVV-X | 0.1 mg |
| Other Products | ||
| 分类 | 产品清单 | 编号 |
| Other Products-Canine Proteins | Canine Fibrinogen | CFib |
| Canine Thrombin | CIIa | |
| Canine Factor IX | CFIX | |
| Canine Factor X | CFX | |
| Canine Factor Xa | CFXa | |
| Other Products-Murine Proteins | Murine Fibrinogen | MFg |
| Murine Antithrombin III | MAT | |
| Murine Thrombin | MIIa | |
| Murine Factor XIII | MFXIII | |
| Murine Plasminogen | MPg | |
| Other Products-Porcine Proteins | Porcine Factor Xa | PFXa |
| Porcine Thrombin | PIIa | |
| Porcine Fibrinogen | PFib | |
| Other Products-Rabbit Proteins | Rabbit Fibrinogen | RbFg |
| Rabbit Factor Xa | RbXa | |
| Rabbit Factor X | RbX | |
| Rabbit Thrombin | RbIIa | |
| Other Products-Rat Proteins | Rat Fibrinogen | RFib |
| Rat Thrombin | RIIa | |
| Rat Factor Xa | RFXa | |
| Other Products-Des-Gla Proteins | Des-Gla-Human Protein C | HPC-GD |
| Des-Gla-Human Activated Protein C | APC-GD | |
| Des-Gla-Human Factor X | HFX-GD | |
| Des-Gla-Human Factor Xaβ | HFXab-GD | |
| Des-Gla-Human Factor VIIa | HFVIIaGD | |
| Des-Gla-Human Prothrombin | HP-GD | |
| Other Products-Inactivated Proteins | Human Thrombin | HTi |
| Human Factor VIIa | HFVIIai | |
| Human Factor IXaß | HFIXai | |
| Human Activated Protein C | APCi | |

艾美捷科技特约代理Exbio公司产品。Exbio公司是捷克著名的抗体生产商,该公司于学术机构展开广泛的合作,在杂交瘤、重组蛋白和抗体方面始终保持研发力度,持续不断地推出新的产品。
抗体产品主要包括以下领域:Human Immunology、Rodent Immunology、Veterinary Reagents、
Cell Biology、Isotype Control Reagents等,此外还有重组蛋白、试剂盒,以及OEM服务。
EXBIO manufactures and supplies antibodies for world-wide distribution. Sales on an OEM basis and in bulk quantity is the core business activity of the company. Strong Research & Development (hybridoma technology, construction of recombinant proteins and antibodies) in co-operation with academic institutions ensures the continuous addition of important new products.
EXBIO entered the antibody market as a spin-off company of Czech Academy of Sciences in 1990. Continuous economic growth resulted in the movement to our own brand new manufacture facility on February 2003.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Exbio"> Exbio
艾美捷科技特约代理F.S.T(Fine Science Tools)公司全系列产品。
F.S.T(Fine Science Tools)公司以追求高质量的产品和优质的服务为目标,为医护和科研人员提供医疗和动物精密手术器械,因而成为全球领先的手术器械生产商和供应商。F. S. T拥有手术剪、手术镊、骨科器械、手术刀及刀片、血管钳、持针钳等10余类共1000余种。
Fine Science Tools is the leading distributor of precision European surgical and microsurgical instruments to the scientific and biomedical research community.
Fine Science Tools公司的主要产品包括:
Scissors
Bone Instruments
Scalpels & Blades
Curettes, Spatulae & Probes
Pins
Wound Closure
Retractors
Vascular Instruments
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Fine Science Tools"> Fine Science Tools
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

SERO生产以下系列专利产品Seronorm™, Pathonorm™ and Autonorm™。除此之外,也为客户提供个性化定制产品。
Seronorm™系列
主要产品包括免疫对照,结合激素,心脏和肿瘤标志物,Seronorm™所有对照血清来源为人,不含防腐剂和稳定剂,产品文档全面,为市场上最常用的仪器提供超过50种分析物的分配值,可提供四个不同临床级别,且每一级别都可单独提供。Seronorm™ Immunoassay Liq low – 含有与临床相当的低水平的醛固酮,雄烯二酮,皮质醇,铁蛋白,IgE,17-OH-孕酮,PSA总量,睾酮,游离T4,TSH,25-OH-维生素D和维生素B12
Pathonorm™ and Autonorm™
Pathonorm™临床化学级对照,不含防腐剂和稳定剂的动物血清,适合大部分临床化学分析,为市面上常用仪器提供超过38种分析物的分配值,有两种临床级别,且都可以单独提供,产品以冻干粉形式提供,货架期长。
Autonorm™
满足绝大部分临床化学实验室正常水平的分析级的高品质对照,不含防腐剂和稳定剂的动物血清,不含Pharmaca。文档齐全,为市场上最常用的仪器提供超过30种分析物的分配值,冻干粉,货架期长。
客户定制产品:
SERO也针对有质量意识的诊断公司,组织提供定制服务,SERO可定制的高品质对照产品如下:
常规血清化学(人或动物基质)
常规尿液化学
脂质
激素
肿瘤标记
心脏标志物
蛋白质
治疗药物
专业和护理点控制(CRP,HbA1C,血红蛋白,葡萄糖)
微量元素和重金属
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="SERO"> SERO
艾美捷科技特约代理ScienCell品牌。
ScienCell公司为研究界提供各种高质量的正常人类和动物细胞、细胞培养基和试剂、基因分析工具、细胞衍生的分子生物学产品、基于细胞的检测试剂盒和干细胞产品。
ScienCell公司产品线包括:
(1)原代细胞:采用ScienCell独有的方法从健康的人和动物组织中分离出来,在早期传代时进行冷冻保存,具有出色的细胞活力。
(2)细胞培养基:ScienCell的各种细胞培养基均为液体形式,包括特殊、经典和补充品种。每种产品均专为原代细胞的最佳营养和生长而设计。
(3)干细胞:干细胞是独特的细胞,具有在体内发育成各种特殊细胞类型的卓越能力,它们的特点是具有自我更新和分化成不同细胞谱系的能力。
(4)遗传学与基因组学:提供定制引物设计和试剂盒服务。
(5)分子生物学:产品:cDNA、基因组DNA、总RNA、MicroRNA、细胞裂解物和细胞沉淀。
(6)基于细胞的检测:ScienCell开发了多种基于细胞的检测检测试剂盒,包括新陈代谢、氧化应激和干细胞等许多领域,并提供酶活性、代谢物水平和细胞生长状态的定量结果。
(7)生长因子和蛋白质:ScienCell提供高质量生长因子、细胞因子和重组蛋白。
< " data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技特约代理ScienCell品牌"> 艾美捷科技特约代理ScienCell品牌
Illumina公司,基因组学研究领域的技术与市场领导者。借助新一代测序(NGS)与基因芯片(MicroArray)技术与平台,秉承“解锁基因组奥秘,推动人类健康事业”的愿景,为全球科研、医疗、制药、公共卫生等领域提供基因组学完整解决方案。Illumina公司主要提供Sequencing Kits、Library Preparation Kits、Cluster Generation & Sequencing Reagents、Microarray Kits、Clinical Research Products和Informatics Products等类型的产品。
Illumina的主要产品包括:
(1)Browse by Area of Interest:
Cancer Genomics Products
Reproductive Health Products
Microbial Genomics Products
Complex Disease Genomics Products
Genetic Health Products
Forensic Genomics Products
Agrigenomics Products
Genomics in Drug Development Products
(2)Browse by System:
HiSeq 2500 Products
HiSeq 3000/HiSeq 4000 Products
HiSeq X Five/HiSeq X Ten Products
iScan Products
iSeq Products
MiniSeq Products
MiSeq Products
MiSeqDx Products
MiSeq FGx Products
NextSeq Products
NovaSeq Products
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
< " data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Illumina"> Illumina地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:15172431432
邮箱:sales@amyjet.com
0.3213